STM JOURNALS

International Journal of
Biomedical Innovations and Engineering

Volume 3, Issue 1, 2025
January–June
DOI (Journal): 10.37591/IJBIE

https://journals.stmjournals.com/ijbie

Review IJBIE

The Contribution of A.I. in Pharmaceutical Software

Mohd. Wasiullah[1], Piyush Yadav[2], Vikash Yadav[3,*], Rajan Yadav[4]

Abstract

The integration of Artificial Intelligence (AI) in pharmaceutical software has significantly transformed drug development, regulatory processes, and clinical management. AI-powered tools are revolutionizing data analysis, predictive modeling, and decision-making, enhancing the efficiency and accuracy of drug discovery and development. This article explores the multifaceted contributions of AI to pharmaceutical software, including its applications in drug screening, personalized medicine, clinical trial optimization, and regulatory compliance. Additionally, we examine how AI is improving the management of patient data, optimizing supply chain processes, and supporting the development of new therapeutic solutions. The article delves into the challenges and ethical dilemmas of integrating AI into the pharmaceutical industry, stressing the importance of transparent practices, safeguarding data privacy, and ensuring thorough validation. This review seeks to present a snapshot of AI's current role and prospects in pharmaceutical software, shedding light on how these innovations are transforming healthcare and medicine.

Keywords: Computer system software, GMP practices, regulatory agency requirements, product quality, healthcare and medicine

INTRODUCTION

The pharmaceutical industry is experiencing a profound shift with the adoption of cutting-edge technologies like artificial intelligence (AI). AI holds the promise of transforming key areas, including drug research, development, production, and distribution. As the complexity of drug discovery increases, traditional methods of analysis and decision-making are often insufficient to keep pace with the growing volume of data and the need for faster, more accurate results. AI-powered pharmaceutical software solutions are stepping in to fill this gap, providing novel approaches to drug design, clinical trials, regulatory compliance, and supply chain management. AI technologies in pharmaceutical software encompass a wide array of tools, from predictive analytics and machine learning models to natural language processing and robotic systems. These tools help streamline drug discovery, reduce time-to-market for new treatments, improve personalized medicine, and optimize operational efficiencies. AI-driven platforms enhancing data analysis, automating repetitive tasks (Figure 1) [1].

DRUG DISCOVERY AND DESIGN

Drug discovery is a complex, time-consuming and expensive process that involves the identification of potential drug candidates that can interact with specific biological targets to treat diseases. Traditional drug discovery methods are often based on trial and error, extensive laboratory work and long clinical trials. The emergence of artificial intelligence (AI), particularly machine learning (ML) and deep learning (DL), has drastically sped up and streamlined the process [2].

***Author for Correspondence**
Vikash Yadav
E-mail: vikashy2561998@gmail.com

[1]Principal, Department of Pharmacy, Prasad Institute of Technology, Jaunpur, Uttar Pradesh, India
[2]Academic Head, Department of Pharmacy, Prasad Institute of Technology, Jaunpur, Uttar Pradesh, India
[3]Lecturer, Department of Pharmacy, Prasad institute of technology, Jaunpur, Uttar Pradesh, India
[4]Scholar, Department of Pharmacy, Prasad Institute of Technology, Jaunpur, Uttar Pradesh, India

Received Date: December 14, 2024
Accepted Date: December 29, 2024
Published Date: February 21, 2025

Citation: Mohd. Wasiullah, Piyush Yadav, Vikash Yadav, Rajan Yadav. The Contribution of A.I. in Pharmaceutical Software. International Journal of Biomedical Innovations and Engineering. 2025; 3(1): 1–11p.

The application of AI in drug discovery and design focuses on predicting the interactions between drug molecules and biological targets, optimizing the properties of drug candidates, and reducing the time required to deliver new therapies to market [3].



Figure 1. Application of Artificial Intelligence in Oral Dosage form.

Identification and Validation of Objectives

AI-based tools help researchers identify potential biological targets (proteins, genes or other molecules) associated with diseases. AI algorithms can sift through vast genomic, proteomic, and clinical datasets to uncover potential targets that might have been missed in the past. Machine learning models can also prioritize these targets based on their relevance to disease and pharmacovigilance, simplifying the early stages of drug discovery [4].

MOLECULAR DESIGN AND OPTIMIZATION

AI enables the design of new molecules by predicting how specific compounds interact with biological targets. Deep learning techniques, including generative adversarial networks (GANs) and reinforcement learning, can design novel molecular structures tailored to specific requirements, such as bioavailability, stability, and safety. These models can also optimize existing compounds, suggesting modifications to improve their effectiveness or reduce their toxicity [5].

- *New Drug Design:* AI can generate completely new molecular entities with desired properties, reducing the need for traditional high-throughput screening of large, complex libraries.
- Structure-Activity Relationship *(SAR) Modeling:* AI algorithms study the link between a compound's chemical structure and its biological activity, aiding in the development of more effective and targeted drugs.

Virtual Exam

AI-based virtual screening techniques simulate the interactions between thousands or even millions of compounds and possible drug targets. By taking advantage of machine learning models, researchers can predict the binding affinity of drug candidates to their targets without having to conduct lengthy laboratory experiments [6].

- *Binding simulations:* AI models predict how small molecules (drugs) fit into protein binding sites, helping to identify compounds with high binding affinity.

Predictive Analytics and Personalized Medicine

Predictive analytics and personalized medicine are two closely related concepts that have the potential to transform the future of healthcare. Predictive analytics involves leveraging data, statistical methods, and machine learning to analyze current and past information to forecast future events or outcomes. In contrast, personalized medicine is a healthcare approach that customizes treatments based on individual patient data, including genetics, lifestyle, and environmental factors, to meet each patient's unique needs [7].

AI in Predictive Analytics for Healthcare

AI, especially machine learning (ML) and deep learning (DL), has become an essential tool for predictive analytics in healthcare. These AI models analyze large multidimensional data sets from electronic health records (EMR), medical images, genomics and clinical trials to predict the course of diseases, identify early signs of disease and recommend preventive measures [8]. There are early detection and diagnosis of diseases. AI models can analyze trends in patient data to predict the onset of illnesses before symptoms appear. For example:

- *Cancer Detection:* AI algorithms can examine medical images, such as CT scans, MRIs, and X-rays, to identify early signs of cancer. These models are trained on extensive image datasets to detect subtle tissue changes that might be overlooked by human doctors.
- *Cardiovascular Risk:* Machine learning models can analyze factors, such as blood pressure, cholesterol levels, family history and lifestyle factors to predict a person's risk of heart disease or stroke. These predictive models can identify people who could benefit from preventive treatments, such as statins or lifestyle changes, before developing serious diseases [9].
- *Treatment Response Prediction:* For diseases, such as cancer or autoimmune diseases, AI can predict how patients will respond to different treatments based on their unique biological data, allowing the selection of the most appropriate therapeutic strategies effective [10]. AI can also predict patient outcomes at the population level, helping healthcare providers optimize resource allocation and planning. For example:
  - *Predicting Hospital Readmissions:* AI models can forecast which patients are more likely to be readmitted to the hospital after being discharged. This helps healthcare providers take preventative measures, such as follow-up care, to reduce readmissions and improve patient outcomes [11].
  - *Demand Forecasting:* AI can predict patient demand for healthcare services, helping hospitals and clinics optimize staffing levels, bed availability and medical supplies [12].
  - *AI and Personalized Medicine:* Personalized medicine tailors' medical treatments to the unique characteristics of each patient, with AI playing a key role by enhancing precision in diagnosis, treatment choices, and ongoing monitoring. there are. Genomics and genetic testing AI have revolutionized genomics, enabling the analysis of complex genetic data [13].
  - *Pharmacogenomics:* AI can examine genetic data to forecast how individual patients will process and react to medications. For example, AI models can identify genetic variations that

influence how a patient responds to chemotherapy, allowing oncologists to select the most effective and least toxic treatments [14].

- o *Gene Editing and Therapy:* AI is also being used to design and optimize gene editing techniques, such as CRISPR, which can be used to correct genetic mutations that cause hereditary diseases. Predictive analytical models help identify the best candidates for gene therapies based on their genetic profiles [15].

PERSONALIZED TREATMENT PLANS

AI enables clinicians to create highly personalized treatment plans by integrating data from multiple sources, including genetic information, clinical history, lifestyle factors, and even social determinants of health. These personalized plans optimize treatment effectiveness while minimizing adverse effects.

Optimizing Clinical Trials

Clinical trials are a fundamental part of the drug development process, helping to assess the safety, effectiveness and optimal use of new treatments. However, traditional clinical trials are long, expensive, and often face challenges related to patient recruitment, data management, and monitoring. Artificial intelligence (AI) is increasingly integrated into the design and management of clinical trials to address these challenges, optimizing various aspects of the trial process and improving the chances of success [16].

AI in Clinical Trial Design

- *Redictive Modeling of Test Results:* AI can help optimize clinical trial design by predicting potential outcomes based on historical data and preclinical results. Using predictive models, researchers can:
- *Predicting Patient Responses:* Machine learning algorithms can analyze data from previous trials to predict how different subgroups of patients might respond to a particular treatment, allowing for more targeted interventions. Predictive modeling also allows the design of adaptive trials, in which study parameters can be changed in real time based on emerging data, helping to maximize the chance of trial success [17].

Optimizing the Selection of Evaluation Criteria

Clinical trials require clearly defined endpoints (ie, the outcomes or measures used to assess the effectiveness of the treatment). AI can help optimize the selection of primary and secondary endpoints by analyzing previous clinical data to determine which parameters are most predictive of treatment success [18].

DRUG REPURPOSE

is the process of identifying new uses for existing drugs already approved for other indications. This includes testing approved or investigational drugs for diseases or conditions outside of their original therapeutic intent. This approach offers a quicker and more cost-efficient method for introducing new treatments to the market compared to creating entirely new drugs from the ground up.

Main Advantages of Drug Repurpose

- *Faster Time to Market:* Because repurposed drugs have already undergone many safety tests and clinical trials, they can often enter clinical development faster than new compounds.
- *Reduced Development Costs:* Drug repurposing significantly reduces the costs associated with pre-clinical studies, safety assessments, and early-stage clinical trials.
- *Reduced Risk:* Existing drugs have known safety profiles, making it less risky to test in new indications, especially in patients with underlying diseases or comorbidities.
- *Respond to Unmet Needs:* Repurposing can help treat diseases for which there are few or no effective treatments, especially rare or complex diseases.

Main Approaches to Drug Reuse

- *Computational Reuse of Drugs:* In silico methods: These involve the use of computational tools, databases and algorithms to predict new potential uses for existing drugs. For example, molecular association studies can identify new targets for a drug, or machine learning algorithms can find associations between drugs and diseases in large data sets (e.g., electronic medical records or genomics) [19].
- *Data Mining:* Using large-scale data from clinical trials, genomics, proteomics and the medical literature to identify new indications for existing drugs.
- *Pharmacological Profile:* The drug can be tested in different disease models to assess its effectiveness against new targets. This may include in vitro testing or animal models. Some companies or academic institutions use high-throughput screening (HTS) to identify drugs that can act on a new target or mechanism of action [20].

Examples of Successful Drug Repurpose

- *Thalidomide:* Originally developed as a sedative, thalidomide was later repurposed to treat multiple myeloma and leprosy after its teratogenic effects were discovered.
- *Sildenafil (Viagra):* Originally developed as a treatment for hypertension and angina, sildenafil was repurposed to treat erectile dysfunction after researchers discovered its effect on penile blood flow.
- *Raloxifene:* Originally approved for the treatment of osteoporosis, tamoxifen has been reported for the prevention of breast cancer, especially in postmenopausal women at risk.
- *Minoxidil:* Originally developed as a treatment for high blood pressure, minoxidil has been repurposed as a treatment for hair loss (Rogaine).
- *Ivermectin:* Originally developed as an antiparasitic, ivermectin has been studied and used to treat diseases, such as COVID-19 (although the evidence is limited in some cases).

Challenges Related to Drug Repurpose

- *Regulatory Approval:* Even if a drug is approved for one indication, obtaining approval for a new indication may require extensive clinical trials, although these trials may be smaller and faster.
- *Intellectual Property (IP) and Patents:* Many repurposed drugs are no longer protected by patents, which can make them less attractive to pharmaceutical companies seeking exclusivity. However, repurpose can sometimes lead to new patent opportunities if the mechanism of action is sufficiently novel.
- *Evidence of Efficacy and Safety:* Just because a drug is safe for one disease does not guarantee its safety or effectiveness for a new disease. Rigorous testing is still required.
- *Market Incentive:* Even if the repurposing of drugs is profitable, it is not always as profitable financially as the development of new successful drugs. Market incentives for repurpose may be weaker, particularly for diseases with smaller patient populations or if the drug is no longer protected by patent.

Steps in the Drug Recycling Process

- *Identification of Potential Drugs:* This can be based on preclinical data, scientific publications or data mining approaches (for example, from clinical trial data, public health data, etc.).
- *Preclinical Testing:* Screening of existing drugs for potential new targets using in vitro or animal models.
- *Clinical Trials:* If preclinical trials are promising, the drug can be tested in clinical trials for its new indication.
- *Approval and Marketing:* Once the processes are complete, the drug can be submitted for regulatory.

Supply Chain Manufacturing Optimization

Drug repurposing is a promising approach for drug development, particularly to address unmet medical needs and accelerate access to therapies. By leveraging existing compounds and repurposing them for new indications, pharmaceutical companies can bring innovative treatments to market more efficiently and cost-effectively [21].

DEMAND FORECASTING AND PLANNING

- *Data analytics and machine learning:* Use advanced data analytics, machine learning and artificial intelligence to predict demand more accurately. This helps reduce overproduction or stock shortages.
- *Collaborative planning:* Share demand forecasts and inventory levels across departments (sales, manufacturing, logistics) and with suppliers to align production schedules with current customer demand [22].

Optimization of Inventory Management

- *Just-in-time (JIT) inventory:* Reduce inventory costs by ordering and producing only what is needed for production when needed.

Poor Production

- *Waste reduction:* Implement lean principles to minimize waste in the manufacturing process, including reducing overproduction, waiting times, transportation, and defects.
- *Kaizen and continuous improvement:* Cultivate a culture of ongoing improvement by encouraging employees to suggest ways to optimize processes.

Production Planning and Resource Optimization

- *Advanced Planning and Scheduling (APS):* Use APS software to optimize the allocation of resources (labor, equipment, materials) in the production process and ensure the best possible use of assets.
- *Flexible Production Systems***:** Design production systems that can quickly switch between product types or increase or decrease production based on fluctuations in demand.

Natural Language Processing (NLP) Data Mining

Especially when dealing with unstructured text data. It allows computers to understand, interpret and analyze human language in a meaningful and actionable way. Here is an overview of how NLP is applied to data mining:

Process Before the Text

- *Tokenization:* break the text into smaller units, such as words or sentences.
- *Stop Word Removal:* Eliminating common words (like “the,” “is,” and “and”) that don’t contribute significant meaning. Rooting and lemmatization: simplifying words to their base form (for instance, “running” becomes “run”).
- *Lowercase:* Convert all text to lowercase to ensure that identical words are treated the same, regardless of their case.

Presentation of the Text

- *Bag of Words (BoW):* Represent text as a set of words, disregarding grammar and word order, but tracking word frequency.
- *TF-IDF (Term Frequency-Inverse Document Frequency):* A statistical method used to assess the significance of a word in a document compared to a larger corpus.
- *Word Embedding:* Employ methods, like Word2Vec, GloVe, or FastText, to represent words in a continuous vector space, capturing their semantic connections.

Feature Extraction

- *Named Entity Recognition (NER):* Identifying entities like names, locations, dates, and other key concepts within the text.
- *Part of Speech Labeling:* assign each word in a sentence to its grammatical category (noun, verb, adjective, etc.).
- *Topic Modeling:* Identifying themes or topics within a large collection of documents, such as using Latent Dirichlet Allocation (LDA).

MEDICINE SAFETY AND PHARMACOVIGILANCE

Medicine safety and pharmacovigilance are essential aspects of the pharmaceutical industry, which aim to ensure that medicines are safe and effective for public use. Pharmacovigilance involves monitoring, detection, evaluation and prevention of adverse effects of pharmaceutical products, while drug safety focuses on minimizing the risks associated with their use [23].

Drug Safety and Pharmacovigilance

Adverse Event Detection and Signal Detection

Pharmacovigilance relies on the collection and analysis of adverse event reports (AERs) from a variety of sources, including clinical trials, health care providers, patients, and regulatory agencies. AI-driven tools, such as machine learning (ML) and natural language processing (NLP), are transforming how these reports are handled.

- *Machine Learning Models:* AI algorithms can detect trends in large volumes of clinical and real-world data, identifying potential safety signals (new or previously unknown adverse reactions) that may warrant further investigation.
- *Natural Language Processing (NLP):* NLP techniques allow AI systems to analyze unstructured text from a variety of sources, such as electronic medical records (EMRs), medical literature, social media, and patient forums, to automatically extract relevant information about adverse drug reactions (ADRs). This process can significantly reduce the time it takes to identify safety issues.
- *Automated Signal Detection:* AI models can automatically flag safety signals based on real-time analysis of data from spontaneous reporting systems, clinical trials, and observational studies. This early detection of potential risks allows for faster regulatory action.

Monitoring Drug Safety in Real Time

AI-based systems enable real-time monitoring of drug safety data, significantly improving safety reporting times. Traditional pharmacovigilance methods may have delays in detecting emerging trends or risks. In contrast, AI can continuously monitor large data sets (such as electronic medical records, social media and insurance claims data) to identify early signs of adverse drug reactions (ADRs).

Predictive Analytics

AI models leverage predictive analytics to estimate the probability of adverse events in various patient groups using historical data. This enables pharmaceutical companies and regulators to take proactive steps before issues escalate.

Integration of Real-World Data

AI facilitates the incorporation of real-world evidence (RWE) from sources like patient-reported outcomes, medical records, and observational studies. This more comprehensive and detailed data helps in identifying adverse reactions that might not have been detected in clinical trials.

The Automation of Administrative Tasks

In the pharmaceutical industry, administrative tasks are frequently time-consuming, repetitive, and susceptible to human error. These tasks include regulatory reporting, document management, claims processing, and supply chain management. By incorporating artificial intelligence (AI) and robotic process automation (RPA) into administrative workflows, pharmaceutical companies can streamline operations, cut costs, and enhance efficiency [24].

Regulatory Compliance and Documentation

Pharmaceutical companies are required to comply with strict regulations set by authorities, such as the FDA, EMA and other international bodies. Artificial intelligence and automation tools are significantly improving the way these companies manage documentation and ensure regulatory compliance.

Automating Regulatory Reporting

AI-powered tools can automate the creation of regulatory documents, such as marketing authorization applications (NDAs), periodic safety update reports (PSURs) and risk management plans (RMP).

CLINICAL TRIAL MANAGEMENT

Clinical trials are complex processes that require meticulous coordination, document tracking, and data analysis. AI can automate certain aspects of clinical trial management, boosting both efficiency and accuracy. Patient recruitment: Finding and enrolling suitable patients for clinical trials is a resource-heavy process, but AI can help streamline this task.

- *Trial Monitoring and Data Management:* AI can automate trial data collection and tracking, track patient progress, manage adverse event reports and ensure trial protocol compliance. Automated data collection minimizes human error and guarantees more accurate and prompt reporting.
- *Document Automation:* AI-powered tools can automate the generation of informed consent forms, clinical trial reports and other necessary documents, reducing the administrative burden for trial managers and ensuring compliance with regulatory requirements.

Supply Chain and Inventory Management

AI is revolutionizing supply chain management by automating many aspects of inventory control, demand forecasting and distribution logistics.

- *Demand Forecasting:* AI-powered predictive analytics can assist pharmaceutical companies in forecasting product demand more accurately by analyzing past sales data, market trends, and external factors like seasonal demand. This helps to optimize production and avoid stockouts or overproduction. Inventory
- *Management:* AI systems can automatically track inventory levels in real time, identify trends in inventory usage, and trigger reordering when inventory levels fall below a certain threshold. This minimizes the risk of human errors in inventory management and ensures prompt restocking [22–24].

Billing, Claims Processing, and Payments

AI is helping pharmaceutical companies automate administrative tasks related to billing, claims processing, and payments, particularly in the healthcare and insurance industries.

- *Claims Processing Automation:* AI can streamline the process of submitting and processing insurance claims by extracting and verifying patient information, treatment codes, and medication details from electronic documents. Machine learning algorithms can identify errors or discrepancies in claims before they are submitted, reducing time spent on corrections and minimizing waste.

Customer service and Communication

Chatbots and AI-powered virtual assistants are transforming customer service and communication in the pharmaceutical industry, especially in the areas of sales and patient care.

- *Customer Service Chatbots:* AI chatbots can handle common customer service requests, such as checking medication availability, providing medication information, or updating patient prescriptions. These virtual assistants can function around the clock, offering instant responses and lightening the workload of human customer service agents.
- *Sales Force Automation:* AI tools can automate various aspects of the sales process, such as managing customer relationships, tracking sales data, and scheduling sales calls. follow up or meetings. Sales reps can focus on priority tasks while AI handles routine administrative tasks.
- *Patient Engagement:* AI can help automate personalized communications with patients, providing them with reminders about medication refills, follow-up appointments, or health monitoring. AI-driven systems can also provide tailored educational materials for each patient, improving adherence to treatment plans. 6. Human resources and employee management.

A.I. In Drug Formulation and Manufacturing

Artificial intelligence (AI) is revolutionizing drug formulation and manufacturing by optimizing processes, improving quality and increasing efficiency throughout the drug manufacturing lifecycle. Below are the main ways AI helps in drug formulation and manufacturing:

Development of Formulation

- *Formulation Property Prediction:* AI can predict the physical, chemical and biological properties of drug formulations before their physical production. Using machine learning (ML) algorithms, AI models can analyze existing data from previous formulations and predict how ingredient or process changes may affect product stability, solubility, bioavailability and final overall effectiveness.
- *Optimizing Drug Formulation:* AI tools can help identify the best combinations of excipients (inactive ingredients) and active pharmaceutical ingredients (APIs) that maximize drug performance. For example, AI can predict how certain excipients affect the release rate of a drug, allowing the creation of more effective controlled-release formulations.
- *Automated Experimentation:* AI can help automate the trial-and-error process of drug formulation, predicting which formulations are most likely to succeed, reducing the need for costly and time-consuming experimental laboratory trials.

Optimization of the Process

- *Predictive Process Control:* AI can optimize drug manufacturing process parameters, such as temperature, pressure, humidity and mixing speed, to ensure they operate in optimal conditions. Machine learning models can be trained on historical production data to predict when adjustments should be made to maintain desired product quality.
- *Real-time Monitoring:* AI-powered sensors and monitoring systems track critical process variables in real-time, providing manufacturers with actionable insights that can be used to prevent deviations from optimal production parameters.
- *Adaptive Manufacturing:* AI can enable adaptive manufacturing, where the manufacturing process can be self-adjusted based on real-time data. This may include adjusting batch sizes, changing formulation parameters, or recalibrating equipment to respond to changes in raw materials or environmental conditions.

Quality Control and Assurance

- *Automated Quality Inspections:* AI-driven computer vision systems are increasingly used in quality control to inspect tablets, capsules or injectable vials for defects, such as cracks, stains or contamination.
- *Defect Prediction:* AI can predict potential defects or quality variations of drugs during production by analyzing historical data from previous batches. This can help manufacturers adjust processes earlier in the production cycle to mitigate problems before they occur and minimize.

CONCLUSIONS

The integration of artificial intelligence (AI) into pharmaceutical software has significantly transformed the industry, providing increased efficiency, accuracy and predictive capabilities. AI-powered tools streamline drug discovery, optimize clinical trials, and support personalized medicine by analyzing large sets of data that humans could not process manually. In addition, AI has revolutionized regulatory compliance and post-market surveillance by detecting adverse drug reactions and ensuring that pharmaceutical products meet safety standards. As AI technologies continue to evolve, their role in pharmaceutical software is expected to grow, providing more advanced solutions for drug development, patient care and operational management. The continued collaboration between AI and the pharmaceutical industry has tremendous potential to improve health outcomes and accelerate innovation in medicine.

REFERENCES

1. Chakraborty C, Sonawane KD, Jain G, Banerjee S. Artificial intelligence in drug development and discovery. Pharm Res. 2020;37(10):196.

2. Joubert SI, Delalonde M, Heghinian K, Al-Shehri M, Zinger S, et al. The impact of artificial intelligence in drug discovery: A comprehensive review. J Pharm Sci. 2022;111(7):1814–1832.
3. Kourou K, Exarchos TP, Exarchos KP, Karamouzis MV, Fotiadis DI. Machine learning applications in cancer prognosis and prediction. Comput Struct Biotechnol J. 2015;13:8–17.
4. Schwaber JS, Searle SR. AI and machine learning in drug development: The path to revolutionizing healthcare. Pharm Innov. 2019;14(3):12–17.
5. Vamathevan J, Clark D, Czodrowski P, Dunham I, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019;18(6):463–477.
6. Wang F, Kesselheim AS, Franklin JM, Ross KM, et al. Artificial intelligence in pharmaceutical research and development. Adv Drug Deliv Rev. 2021;170:3–19.
7. Silver D, Huang A, Maddison CJ, Guez A, Sifre L, et al. Mastering the game of Go with deep neural networks and tree search. Nature. 2016;529(7587):484–489.
8. Huang S, Yang J, Fong S, Zhao Q. Artificial intelligence for drug discovery and development: A review of current applications. J Clin Pharmacol. 2020;60(7):922–937.
9. Liu X, Faes L, Kale AU, Wagner SK, et al. AI-driven drug discovery: The state of the art. Drug Discov Today. 2020;25(8):1405–1415.
10. Zhou Y, Yeung W, Wang Y, Zhang S. Artificial intelligence in pharmacovigilance: Current applications and future directions. Pharmacol Res. 2022;180:106195.
11. Rodrigues T, Bernardes GJ, Lam K, Orgogozo A, et al. Machine learning in pharmaceutical research and drug development. Eur J Med Chem. 2019;163:48–60.
12. Bender A, Cortes-Ciriano I, Chen H, et al. Applications of artificial intelligence in drug discovery: A review. J Med Chem. 2018;61(22):9631–9641.
13. Vidal D, Pastor M, Baqué P, et al. Artificial intelligence in drug discovery: A systematic review and future perspectives. J Transl Med. 2020;18(1):1–12.
14. Ekins S, Puhl AC, Zorn KM, Lane TR, et al. The role of artificial intelligence in drug discovery and development. Expert Opin Drug Discov. 2019;14(10):1215–1226.
15. Vamathevan J, Clark D, Czodrowski P, Dunham I, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019;18(6):463–477.
16. Chen H, Engkvist O, Wang Y, Olivecrona M, Blaschke T. The rise of deep learning in drug discovery. Drug Discov Today. 2018;23(6):1241–1251.
17. Sliwoski G, Kothiwale S, Meiler J, Lowe EW. Computational methods in drug discovery and development. Pharmacol Rev. 2014;66(1):18–48.
18. Kaiser D, Rodriguez JA, Schuler J, Fetz V, et al. AI for precision medicine in the pharmaceutical industry: A review. Comput Biol Chem. 2020; 85:107224.
19. Ramsundama R, Owens DR, Dagum P. Massively parallel methods for drug discovery. J Chem Inf Model. 2017;57(10):2194.
20. Zhou Y, Wang Y, Zhang S, Du X. Artificial intelligence in drug discovery and development: A critical review of the status. J Pharm Innov. 2021; 26:75–88.
21. Ochoa D, Shah D, Besnard J, et al. Applications of machine learning in drug development: A focus on the discovery process. Expert Opin Drug Discov. 2019;14(9):965–975.
22. Rosenblatt M, Kimmelman J, Lemke J, Friberg L. Artificial intelligence in clinical trials: Applications and potential benefits. Pharm Med. 2020;34(5):329–337.
23. Garcia S, Verhoeven D, Sharma T, et al. Applications of artificial intelligence in the pharmacogenomics of drug response. Hum Genomics. 2021;15(1):9.
24. Kermani BG, Brocchini S, Penketh PG, et al. AI for drug repositioning: An overview of methods and applications. Pharmacol Ther. 2022; 227:1078.

